Source 1review2020Exploration of Targeted Anti-tumor Therapy
Toolkit/PROTAC
PROTAC
Also known as: proteolysis-targeting chimera, PROteolysis TArgeting Chimera, proteolysis-targeting chimeras, PROteolysis TArgeting Chimeras
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an "anchor" to bind to an E3 ubiquitin ligase and a "warhead" to bind to a protein of interest, connected by a chemical linker.
Usefulness & Problems
Why this is useful
PROTACs are the central targeted protein degrader modality discussed by this review. They are described in the supplied summary as heterobifunctional degraders that recruit E3 ligases for targeted protein degradation.; targeted protein degradation; induced degradation of disease-relevant proteins; drug discovery strategies that recruit E3 ligases to targets; PROTACs are engineered molecules that induce degradation of pathogenic proteins through the ubiquitin-proteasome system. The review presents them as the degradation platform combined with photopharmacology.; targeted degradation of pathogenic proteins; addressing targets in the undruggable proteome; event-driven pharmacology; A PROTAC is a heterobifunctional degrader that links an E3 ligase-binding anchor to a target-binding warhead through a chemical linker. The review frames it as a modality for targeted protein knockdown.; knock down of proteins using heterobifunctional degraders
Source:
PROTACs are the central targeted protein degrader modality discussed by this review. They are described in the supplied summary as heterobifunctional degraders that recruit E3 ligases for targeted protein degradation.
Source:
targeted protein degradation
Source:
induced degradation of disease-relevant proteins
Source:
drug discovery strategies that recruit E3 ligases to targets
Source:
PROTACs are engineered molecules that induce degradation of pathogenic proteins through the ubiquitin-proteasome system. The review presents them as the degradation platform combined with photopharmacology.
Source:
targeted degradation of pathogenic proteins
Source:
addressing targets in the undruggable proteome
Source:
event-driven pharmacology
Source:
A PROTAC is a heterobifunctional degrader that links an E3 ligase-binding anchor to a target-binding warhead through a chemical linker. The review frames it as a modality for targeted protein knockdown.
Source:
targeted protein degradation
Source:
knock down of proteins using heterobifunctional degraders
Problem solved
This modality addresses the problem of removing a protein target through induced degradation rather than only modulating it by occupancy. The review is framed around targeted protein degradation and clinical translation.; enables elimination of target proteins rather than simple occupancy-based inhibition; provides a modality for recruiting ubiquitin ligase machinery to a protein of interest; They offer a way to eliminate pathogenic proteins and may extend drug discovery toward the undruggable proteome. The abstract frames this as event-driven pharmacology.; degrading pathogenic proteins rather than only inhibiting them; expanding intervention options for difficult-to-drug targets; It enables targeted protein degradation as a therapeutic and discovery modality. The review presents this as an alternative way to knock down proteins.; provides a modality for targeted degradation rather than simple occupancy-based inhibition
Source:
This modality addresses the problem of removing a protein target through induced degradation rather than only modulating it by occupancy. The review is framed around targeted protein degradation and clinical translation.
Source:
enables elimination of target proteins rather than simple occupancy-based inhibition
Source:
provides a modality for recruiting ubiquitin ligase machinery to a protein of interest
Source:
They offer a way to eliminate pathogenic proteins and may extend drug discovery toward the undruggable proteome. The abstract frames this as event-driven pharmacology.
Source:
degrading pathogenic proteins rather than only inhibiting them
Source:
expanding intervention options for difficult-to-drug targets
Source:
It enables targeted protein degradation as a therapeutic and discovery modality. The review presents this as an alternative way to knock down proteins.
Source:
provides a modality for targeted degradation rather than simple occupancy-based inhibition
Problem links
degrading pathogenic proteins rather than only inhibiting them
LiteratureThey offer a way to eliminate pathogenic proteins and may extend drug discovery toward the undruggable proteome. The abstract frames this as event-driven pharmacology.
Source:
They offer a way to eliminate pathogenic proteins and may extend drug discovery toward the undruggable proteome. The abstract frames this as event-driven pharmacology.
enables elimination of target proteins rather than simple occupancy-based inhibition
LiteratureThis modality addresses the problem of removing a protein target through induced degradation rather than only modulating it by occupancy. The review is framed around targeted protein degradation and clinical translation.
Source:
This modality addresses the problem of removing a protein target through induced degradation rather than only modulating it by occupancy. The review is framed around targeted protein degradation and clinical translation.
expanding intervention options for difficult-to-drug targets
LiteratureThey offer a way to eliminate pathogenic proteins and may extend drug discovery toward the undruggable proteome. The abstract frames this as event-driven pharmacology.
Source:
They offer a way to eliminate pathogenic proteins and may extend drug discovery toward the undruggable proteome. The abstract frames this as event-driven pharmacology.
provides a modality for recruiting ubiquitin ligase machinery to a protein of interest
LiteratureThis modality addresses the problem of removing a protein target through induced degradation rather than only modulating it by occupancy. The review is framed around targeted protein degradation and clinical translation.
Source:
This modality addresses the problem of removing a protein target through induced degradation rather than only modulating it by occupancy. The review is framed around targeted protein degradation and clinical translation.
provides a modality for targeted degradation rather than simple occupancy-based inhibition
LiteratureIt enables targeted protein degradation as a therapeutic and discovery modality. The review presents this as an alternative way to knock down proteins.
Source:
It enables targeted protein degradation as a therapeutic and discovery modality. The review presents this as an alternative way to knock down proteins.
Published Workflows
Objective: Accelerate identification of optimized PROTACs by moving from empirical linker trial-and-error toward rational linker design informed by linker classes, design principles, and ternary-complex understanding.
Why it works: The review states that linker length and composition strongly affect PROTAC properties and bioactivity, so a design workflow that explicitly considers linker principles and ternary-complex behavior should better guide optimization than unguided empirical iteration.
targeted protein degradationternary complex structureternary complex dynamicslinker class selectionPROTAC assemblycomputational methodsstructural methods
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
Degradatione3 ligase recruitmentevent-driven pharmacologyheterobifunctional target engagementTranslation Controlubiquitin-proteasome-system-mediated degradationTechniques
No technique tags yet.
Target processes
degradationlocalizationtranslationInput: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: regulatorswitch architecture: recruitment
Execution of the modality requires a target-binding element and access to recruited E3 ligase machinery. The supplied summary specifically highlights E3 ligase recruitment as a core component.; requires recruitment of an E3 ligase as part of the degrader mechanism; the supplied summary indicates ligase choice is an important design variable; Their function depends on the ubiquitin-proteasome system. In the context of this review, they can also be coupled to light-responsive control strategies.; requires access to the ubiquitin-proteasome system; Implementation requires two binding ligands and a chemical linker assembled into one molecule. Product behavior depends on linker length and composition.; requires an E3 ligase-binding anchor, a target-binding warhead, and a connecting chemical linker; linker length and composition critically influence performance
The provided evidence does not support detailed claims about which targets, tissues, or delivery settings are reliably solved by PROTACs. Specific failure modes are not recoverable from the payload alone.; the provided payload does not include abstract or full-text details needed to support specific performance or design-rule claims; The abstract indicates that simply assembling anchor and warhead is not sufficient to guarantee activity, because linker-dependent physicochemical and bioactivity issues remain major bottlenecks.; bioactivity and physicochemical properties depend strongly on linker design; current design has relied heavily on trial-and-error optimization
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2review2022Nature Reviews Drug Discovery
Source 3review2021Frontiers in Chemistry
Ranked Claims
The review scope includes clinical translation of PROTAC targeted protein degraders.
This review is centered on heterobifunctional PROTACs within the broader targeted protein degradation field and also discusses adjacent modalities such as molecular glues.
PROTACs have the potential to target the undruggable proteome via event-driven pharmacology.
This approach has the potential to target the undruggable proteome via event-driven pharmacology.
The combination of photopharmacology and PROTACs has recently gained momentum for discovery and development of new therapies.
Recently, the combination strategy of photopharmacology and PROTACs has gained tremendous momentum for its use in the discovery and development of new therapies.
PROTACs are engineered to degrade pathogenic proteins through the ubiquitin-proteasome system for disease treatment.
Proteolysis-targeting chimeras (PROTACs) are an advanced technology engineered to degrade pathogenic proteins through the ubiquitin-proteasome system for disease treatment.
The review covers photoPROTACs and discusses both advantages and disadvantages as a biological tool as well as challenges in clinical settings.
Herein, we provide an overview of the new and vibrant research on photoPROTACs, discuss the advantages and disadvantages of this approach as a biological tool, and outline the challenges it faces in a clinical setting.
In PROTACs, linker length and composition critically influence physicochemical properties and bioactivity.
The PROTAC field is shifting from synthetically tractable alkyl and polyethylene glycol linkers toward more sophisticated functional linkers.
Approval Evidence
3 sources6 linked approval claimsfirst-pass slug protac
The review title explicitly names "PROTAC targeted protein degraders" and the supplied summary states that the article is centered on heterobifunctional PROTACs, clinical translation, E3 ligase recruitment, and adjacent degrader modalities.
Source:
Proteolysis-targeting chimeras (PROTACs) are an advanced technology engineered to degrade pathogenic proteins through the ubiquitin-proteasome system for disease treatment. This approach has the potential to target the undruggable proteome via event-driven pharmacology.
Source:
PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an "anchor" to bind to an E3 ubiquitin ligase and a "warhead" to bind to a protein of interest, connected by a chemical linker.
Source:
clinical translationsupports
The review scope includes clinical translation of PROTAC targeted protein degraders.
Source:
review scopesupports
This review is centered on heterobifunctional PROTACs within the broader targeted protein degradation field and also discusses adjacent modalities such as molecular glues.
Source:
capability summarysupports
PROTACs have the potential to target the undruggable proteome via event-driven pharmacology.
This approach has the potential to target the undruggable proteome via event-driven pharmacology.
Source:
field momentumsupports
The combination of photopharmacology and PROTACs has recently gained momentum for discovery and development of new therapies.
Recently, the combination strategy of photopharmacology and PROTACs has gained tremendous momentum for its use in the discovery and development of new therapies.
Source:
mechanism summarysupports
PROTACs are engineered to degrade pathogenic proteins through the ubiquitin-proteasome system for disease treatment.
Proteolysis-targeting chimeras (PROTACs) are an advanced technology engineered to degrade pathogenic proteins through the ubiquitin-proteasome system for disease treatment.
Source:
design principlesupports
In PROTACs, linker length and composition critically influence physicochemical properties and bioactivity.
Source:
Comparisons
Source-stated alternatives
The supplied summary explicitly places molecular glues as an adjacent degrader modality. The broader topic of targeted protein degradation is also presented as the parent space around PROTACs.; The abstract contrasts PROTACs with the added light-control strategy of photopharmacology rather than naming other degrader classes.; The abstract contrasts traditional trial-and-error linker selection with more rational, computation- and structure-informed design strategies.
Source:
The supplied summary explicitly places molecular glues as an adjacent degrader modality. The broader topic of targeted protein degradation is also presented as the parent space around PROTACs.
Source:
The abstract contrasts PROTACs with the added light-control strategy of photopharmacology rather than naming other degrader classes.
Source:
The abstract contrasts traditional trial-and-error linker selection with more rational, computation- and structure-informed design strategies.
Source-backed strengths
review scope indicates broad relevance across historical, mechanistic, and translational targeted degradation efforts; explicitly connected to clinical translation in the supplied summary; engineered to degrade pathogenic proteins through the ubiquitin-proteasome system; has potential to target the undruggable proteome; operates via event-driven pharmacology; emerged as a new modality for knock down of a range of proteins; first agents have reached clinical evaluation
Source:
review scope indicates broad relevance across historical, mechanistic, and translational targeted degradation efforts
Source:
explicitly connected to clinical translation in the supplied summary
Source:
engineered to degrade pathogenic proteins through the ubiquitin-proteasome system
Source:
has potential to target the undruggable proteome
Source:
operates via event-driven pharmacology
Source:
emerged as a new modality for knock down of a range of proteins
Source:
first agents have reached clinical evaluation
Compared with molecular glues
The supplied summary explicitly places molecular glues as an adjacent degrader modality. The broader topic of targeted protein degradation is also presented as the parent space around PROTACs.
Shared frame: source-stated alternative in extracted literature
Strengths here: review scope indicates broad relevance across historical, mechanistic, and translational targeted degradation efforts; explicitly connected to clinical translation in the supplied summary; engineered to degrade pathogenic proteins through the ubiquitin-proteasome system.
Relative tradeoffs: the provided payload does not include abstract or full-text details needed to support specific performance or design-rule claims; bioactivity and physicochemical properties depend strongly on linker design; current design has relied heavily on trial-and-error optimization.
Source:
The supplied summary explicitly places molecular glues as an adjacent degrader modality. The broader topic of targeted protein degradation is also presented as the parent space around PROTACs.
Compared with proteolysis targeting chimera
The supplied summary explicitly places molecular glues as an adjacent degrader modality. The broader topic of targeted protein degradation is also presented as the parent space around PROTACs.; The abstract contrasts PROTACs with the added light-control strategy of photopharmacology rather than naming other degrader classes.
Shared frame: source-stated alternative in extracted literature
Strengths here: review scope indicates broad relevance across historical, mechanistic, and translational targeted degradation efforts; explicitly connected to clinical translation in the supplied summary; engineered to degrade pathogenic proteins through the ubiquitin-proteasome system.
Relative tradeoffs: the provided payload does not include abstract or full-text details needed to support specific performance or design-rule claims; bioactivity and physicochemical properties depend strongly on linker design; current design has relied heavily on trial-and-error optimization.
Source:
The supplied summary explicitly places molecular glues as an adjacent degrader modality. The broader topic of targeted protein degradation is also presented as the parent space around PROTACs.
Source:
The abstract contrasts PROTACs with the added light-control strategy of photopharmacology rather than naming other degrader classes.
Ranked Citations
- 1.
- 2.
- 3.